Protalix BioTherapeutics Inc. hired a financial adviser to help it explore alternatives and potential partnerships to maximize shareholder value.
Protalix President and CEO Dror Bashan said the Israel-based biotechnology company aims to improve its capital structure, pursue strategic partnerships and move its pipeline toward commercialization.
The company develops protein-based therapies using its proprietary ProCellEx technology.
Protalix is looking for potential partners for its pipeline candidates including OPRX-106 and alidornase alfa, as well as partnerships that will use other companies' medicines in combination with its ProCellEx platform.
